Cargando…

Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer

BACKGROUND: Checkpoint inhibitors are integral to non-small-cell lung cancer treatment. Existing data suggests that nutritional status may play a role in antitumor immunity. MATERIALS & METHODS: This retrospective study of 106 non-small-cell lung cancer patients who started checkpoint inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Chung-Shien, Devoe, Craig E, Zhu, Xinhua, Fishbein, Joanna Stein, Seetharamu, Nagashree
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186851/ https://www.ncbi.nlm.nih.gov/pubmed/32346405 http://dx.doi.org/10.2217/lmt-2020-0008

Ejemplares similares

Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer
por: Newman, James, et al.
Publicado: (2020)

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
por: Lee, Chung-Shien, et al.
Publicado: (2021)

Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
por: Fraser, Madison, et al.
Publicado: (2023)

Epidemiology and clinicopathological features of lung cancer in patients with prior history of breast cancer
por: Wang, Kevin Y, et al.
Publicado: (2021)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
por: Lee, Chung-Shien, et al.
Publicado: (2020)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu, Nagashree, et al.
Publicado: (2017)

Disparities in lung cancer screening rates among the Hispanic/LatinX population
por: Olazagasti, Coral, et al.
Publicado: (2021)

Disparities in Lung Cancer Screening in Puerto Rico: A United States Colony with Unequal Benefits
por: Olazagasti, Coral, et al.
Publicado: (2021)

Lung cancer screening guidelines are clear but are they being followed?
por: Olazagasti, Coral, et al.
Publicado: (2020)

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges
por: Oduah, Eziafa I., et al.
Publicado: (2022)

One size does not fit all: Evaluating disparities in lung cancer screening eligibility amongst the Hispanic population
por: Olazagasti, Coral, et al.
Publicado: (2022)

Implementing physician education to increase lung cancer screening uptake
por: Olazagasti, Coral, et al.
Publicado: (2023)

An Atypical Presentation of Lichen Planus-Like Reaction from Pembrolizumab
por: Lee, Matthew, et al.
Publicado: (2019)

Optimizing Tissue Use: A Step-wise Approach to Diagnosing Squamous Cell Lung Carcinoma on Small Biopsies
por: Olazagasti, Coral, et al.
Publicado: (2020)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Missed Opportunities? An Observational Analysis of Lung Cancer Screening Utilization Amongst Patients With Lung Cancer
por: Olazagasti, Coral, et al.
Publicado: (2022)

Impact of Family and Social Network on Tobacco Cessation Amongst Cancer Patients
por: Neumann, Melissa, et al.
Publicado: (2021)

SAT-LB102 When the Answer Is Not in the First Look: An Unusual Presentation of Follicular Thyroid Carcinoma
por: Bernabe Ramirez, Carolina, et al.
Publicado: (2019)

Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
por: Runcie, Karie, et al.
Publicado: (2018)

Radiation recall pneumonitis in the setting of immunotherapy and radiation: a focused review
por: McGovern, Kerri, et al.
Publicado: (2019)

Harmine loaded Au@MSNs@PEG@Asp6 nano-composites for treatment of spinal metastasis from lung adenocarcinoma by targeting ANXA9 in vivo experiment
por: Wang, Houlei, et al.
Publicado: (2023)

Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma
por: Sun, Tao, et al.
Publicado: (2023)

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
por: Valero, Cristina, et al.
Publicado: (2021)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
por: Tinker, Anna V., et al.
Publicado: (2023)

Pretreatment eosinophil counts as a predictive biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors
por: Takeuchi, Eiji, et al.
Publicado: (2023)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

Prognostic Effect of the Controlling Nutritional Status Score in Patients With Esophageal Cancer Treated With Immune Checkpoint Inhibitor
por: Chang, Lele, et al.
Publicado: (2022)

Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
por: Zhang, Zhibo, et al.
Publicado: (2020)

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
por: Lim, Sung Won, et al.
Publicado: (2019)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Deep learning predicts immune checkpoint inhibitor-related pneumonitis from pretreatment computed tomography images
por: Tan, Peixin, et al.
Publicado: (2022)

Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2020)

Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors
por: Mahiat, Cédric, et al.
Publicado: (2023)

Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
por: Bianco, Andrea, et al.
Publicado: (2019)

A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report
por: Wang, Carol, et al.
Publicado: (2023)

Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer
por: Qin, Angel, et al.
Publicado: (2016)

Prognostic significance of pretreatment controlling nutritional status score in urological cancers: a systematic review and meta‐analysis
por: Niu, Xinhao, et al.
Publicado: (2021)

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)

Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study
por: Hur, Joon Young, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a77klrv0lunmi3vmd4fhh1dm41